Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name SMARCA4 loss
Gene Variant Detail

SMARCA4 loss (loss of function)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
SMARCA4 loss Advanced Solid Tumor not applicable N/A Preclinical Emerging In a preclinical study, siRNA knockdown of BRM in SMARCA4-deficient tumor cells resulted in decreased growth and viability, suggesting that inhibition of BRM may be a promising therapeutic approach for targeting tumors with SMARCA4 loss (PMID: 23872584). 23872584
SMARCA4 loss lung non-small cell carcinoma sensitive Tozasertib Preclinical - Cell culture Actionable In a preclinical study, non-small cell lung cancer cell lines with SMARCA4 loss demonstrated increased sensitivity to Tozasertib (VX-680), compared to cell lines expressing wild-type SMARCA4, in culture (Cancer Res July 15 2016 (76) (14 Supplement) LB-318). detail...
SMARCA4 loss Advanced Solid Tumor predicted - sensitive PRT7732 Preclinical - Cell culture Actionable In a preclinical study, PRT7732 inhibited proliferation of SMARCA4-deficient cancer cell lines in culture (Cancer Res (2024) 84 (6_Supplement): 4503). detail...
SMARCA4 loss lung cancer predicted - sensitive PRT7732 Preclinical Actionable In a preclinical study, PRT7732 inhibited tumor growth in a SMARCA4-deficient lung cancer xenograft model (Cancer Res (2024) 84 (6_Supplement): 4503). detail...